World's first medical networking and resource portal

Community Weblogs

Aug24

STARTTING TB PROPHYLAXSIS WITH ISONIAZID IN HIV SERIOUS PATIENTS PREVENT TB AND DEATH SAME WAY ARV IS MUST FOR TB PATIENTS WITH HIV - BETTER RESULT LESS MORBIDITY MORTALITY

PROF.DRRAM ,HIV/AIDS,SEX Diseases, Hepatitis .& Deaddiction Expert
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/profdrram
FOLLOW ON TWITTER:www.twitter.com/profdrram

Isoniazid preventive therapy is as effective in staving off tuberculosis as preemptively treating patients with HIV for tuberculosis, research results released here this morning showed. The findings came in one of a series of presentations this morning highlighting challenges posed by tuberculosis to the lives and well-being of people living with HIV, and failures to use proven interventions.
Mina Hosseinipour presented results from an AIDS Clinical Trial Group study that compared the impact of antiretroviral therapy and TB treatment to antiretroviral therapy and 6 months of isoniazid preventive therapy on severely immunosuppressed people with HIV. The study aimed to determine if automatically putting these individuals on TB treatment would more effectively reduce their chances of dying or developing tuberculosis compared to TB preventive therapy. The study found that both TB treatment and TB preventive therapy reduced the risks of acquiring tuberculosis or of dying, and both interventions had very similar results. The bottom line is that the study confirmed that TB preventive therapy is effective even in persons with HIV with severe immunosuppression and works as well as automatically treating these individuals for tuberculosis. The study authors conclude that automatic TB treatment in those without symptoms or confirmed TB results provides no added benefit.
The catch, as reported through two other presentations in the session is that TB preventive therapy has a critical but temporary impact on the risk of developing tuberculosis in countries with huge burdens of HIV and tuberculosis -- a period of about one year according to a study presented at the session from South Africa. Most high burden countries in sub-Saharan Africa have made little or limited progress in providing TB preventive therapy to people with HIV, presentations showed. Annabel Baddeley from the World Health Organization presented data from 14 African counties indicating that only four had implemented TB preventive therapy as part of the standard of care for people with HIV and even those countries had done so in a very limited way. According to Baddeley, there are at least 866,000 people living with HIV in these 14 countries who have not been started on TB preventive therapy. There are 129,849 people co-infected with HIV and tuberculosis who have not yet been initiated on HIV treatment, despite numerous studies documenting the role of antiretroviral therapy of reducing the risk of tuberculosis among persons with HIV and the risk of dying from TB as well as very clear WHO guidelines.



Comments (0)  |   Category (Allergy & Immunology)  |   Views (736)

Community Comments
User Rating
Rate It


Post your comments

 
Browse Archive